Dr. King-Smith has worked in the pharmaceutical industry for the last 20 years, mainly in the field of topical prescription products. He helped establish fqubed, a company that pioneered the use of high throughput experimentation in the field of topical formulation development. fqubed was acquired by Nuvo Research in 2005. At Nuvo, Dominic served in executive positions in new product and strategic planning. He played a key role in developing Pennsaid 2%, currently the top selling topical product on the US market. Subsequently,he served as Crescita’s VP Corporate Development where he was responsible for out licensing the topical product Pliaglis to commercialization partners in the US and Europe. Dominic was appointed as EnZen’s CEO in April 2021. He holds BA and PhD in theoretical physics from Cambridge University. His scientific accomplishments include co-authoring two scientific journal papers with more than 1,000 citations and he is an inventor on 20 issued US patents.

Dr. Jadhav is a Pharmaceutical Technologist with a PhD in chemistry from the State University of New York at Albany. He has spent over 10 years in New York and Mumbai developing new diagnostic kits, and pharmaceutical products with complex delivery systems. He has previously worked with Encube Ethicals and Cipla in Mumbai and Capital Biotech in NY. He is an inventor on many US patents and has authored several scientific publications.

Mr. Mehul Shah is a graduate in pharmacy and a Mumbai bred entrepreneur with more than 30 years of experience in the pharmaceutical industry. He is a founder of Encube Ethicals Pvt Ltd – a parent organization to EnZen Therapeutics. His passion & expertise in topical semisolid formulations has positioned Encube as a global leader in manufacturing dermatological dosage forms. He was awarded Emerging Entrepreneur of the Year at the Indian Pharma Awards 2015.

Mr. Pratik Kamani is a Pharmacist with an MBA from NMIMS, Mumbai and has spent the past 9 years at Encube Ethicals Pvt Ltd. He has played several different roles in the organizational group, and spearheads the strategic and commercial functions for the futuristic growth of the company. Mr. Kamani has led the transformation of the company over the past 5 years, from a CDMO to a full-scale generic commercialization organization, including building teams and offices in the US and acquiring Tioga Research, Inc.

Mr. Kirit Vora is a commerce graduate with a vast experience of 37 years in accounting & finance. Mr. Vora provides leadership and strategic oversight to the organization and has headed several high-impact organization-wide projects enabling strategic business partnering, cost improvements, realization of efficiencies, automation, and best practice in governance.

Mr. Yon is a seasoned healthcare executive with an extensive background in dermatology. His previous roles include executive positions with Pfizer, Solvay, Alcon, and most notably as Chief Executive Officer of Galderma for 17 years. During his time at Galderma, Mr. Yon built the company from its initial spin out from Alcon to be a world leader in ethical dermatology. Galderma currently has over 3500 employees and $2.85 Billion in revenue.

Dr. Janusz Czernielewski worked at Galderma for more than 30 years in various positions from R&D to commercial. He held management positions in Galderma R&D in Sophia Antipolis, Galderma UK, Galderma US, Galderma HQ and Nestlé Skin Health and served on Nestlé Skin Health's executive Boards. His last position was as Vice President of Medical Affairs.

Mr. Dalessandro is a new product development leader and innovator who has developed and commercialized over 20 medical devices for the cardiovascular, surgical, orthopedic, diagnostics and consumer markets. He was a pioneering member of the Johnson & Johnson startup venture and held several leadership positions in research & development and project management during his 30+ year career with several Johnson & Johnson operating companies.